Lorundrostat + Placebo
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Obstructive Sleep Apnea
Conditions
Obstructive Sleep Apnea, Hypertension
Trial Timeline
Feb 28, 2025 → Dec 29, 2025
NCT ID
NCT06785454About Lorundrostat + Placebo
Lorundrostat + Placebo is a phase 2 stage product being developed by Mineralys Therapeutics for Obstructive Sleep Apnea. The current trial status is completed. This product is registered under clinical trial identifier NCT06785454. Target conditions include Obstructive Sleep Apnea, Hypertension.
What happened to similar drugs?
20 of 20 similar drugs in Obstructive Sleep Apnea were approved
Approved (20) Terminated (2) Active (0)
✅Arformoterol Tartrate Inhalation Solution + Arformoterol Tartrate Inhalation Solution + PlaceboSumitomo PharmaApproved
Hype Score Breakdown
Clinical
12
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06785454 | Phase 2 | Completed |
| NCT05968430 | Phase 3 | Active |
Competing Products
20 competing products in Obstructive Sleep Apnea